LIVE

BCRX

BioCryst Pharmaceuticals, Inc.

BCRX

NASDAQ·Healthcare·Biotechnology·Mkt cap $2.0B

$9.84

▲ +1.97%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$6.00 - $10.94

P/E

-5.52

Fwd P/E

36.00

Beta

0.56

Div Yield

0.00%

Avg Vol

5.0M

Shares Out

209.9M

Mkt Cap

$2.0B

Price action

Price chart

Up 7.0% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

3 reasons

  • Proprietary oral small-molecule drug discovery platform with focus on protease and complement inhibitors
  • Established commercial infrastructure with FDA-approved marketed products generating recurring revenue
  • Strategic partnerships with major pharmaceutical companies (Seqirus, Shionogi, Mundipharma) and government agencies (NIAID, BARDA) providing validation and development support
▼

Bear Case

2 risks

  • Low volatility (beta 0.6).
  • Premium valuation to Biotech & Therapeutics peers

Growth

Turning profitable

Expansion of ORLADEYO market penetration in hereditary angioedema patient population

Value

Premium valuation to Biotech & Therapeutics peers

Momentum

Strong

+7.0% over 3m

Quality

Thin

Strong fundamentals

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Apr 30, 2026

“
Q2 26 RECAP

MAY 6, 2026

Reported EPS of -$2.98 vs $0.06 consensus (-5066.7% surprise). Revenue of $156.4M vs $151.1M expected (+3.5%).

EPS miss
Rev beat +3.5%

EPS surprise · last 4Q

0 of 1 beats

Q2 26

-5066.7%

Next: Apr 30, 2026

Revenue trend · last 8Q

—

—

+41%

+57%

+49%

+36%

+209%

+7%

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$109.3M

$117.1M

$131.5M

$145.5M

$163.4M

$159.4M

$406.6M

$156.4M

Margins · last 8Q

Gross

—

Operating

—

Profit

-461.5%

View full earnings history →

Wall Street consensus

6 analysts · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

6

100%

Hold

0%

Sell

0%

Median Price Target

—

Latest: Jefferies · Jun 30, 2026

View full analyst page →

vs Industry

How BCRX stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.